A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)
Stopped Early discontinuation based on strategic sponsor decision not driven by any safety concerns.
Conditions
- Pleural Mesothelioma
- Non-small Cell Lung Cancer
Interventions
- DRUG: THOR-707
- DRUG: Pembrolizumab
Sponsor
Sanofi
Collaborators